Inactive Instrument

Radius Health, Inc.

Equities

RDUS

US7504692077

Biotechnology & Medical Research

Radius Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 09, 2022 at 08:02 am EDT

Radius Health, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 58.29 million compared to USD 51.8 million a year ago. Net loss was USD 12.73 million compared to USD 16.81 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.35 a year ago.
For the six months, revenue was USD 101.44 million compared to USD 108.06 million a year ago. Net loss was USD 31.01 million compared to USD 32.56 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.69 a year ago.

Latest news about Radius Health, Inc.

EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Radius Health, Inc for Binosto for the United States	23-09-19	CI
Radius Health, Inc. Announces the Appointment of Al Medwar as Senior Vice President and Corporate Development	23-07-27	CI
Radius Health, Inc. Appoints Erika Tooman as Senior Vice President/ General Counsel	23-04-06	CI
Theramex Enters into an Exclusive Licensing Agreement with Radius Health Inc, to Commercialise ELADYNOS in the European Economic Area, United Kingdom, Australia and Brazil	23-03-20	CI
Radius Health, Inc. announced that it has received funding from Webster Equity Partners, LLC	22-12-30	CI
Radius Health's Tymlos® (Abaloparatide) Receives U.S. FDA Approval as A Treatment to Increase Bone Density in Men with Osteoporosis At High Risk for Fracture	22-12-20	CI
Ambrx Biopharma Names Kate Hermans Interim CEO	22-08-16	MT
Radius Health, Inc. Announces Board Changes	22-08-15	CI
Radius Health, Inc. Enters into Credit Agreement	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Composite Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P TMI Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Global BMI Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Biotechnology Select Industry Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Biotechnology Index	22-08-10	CI
Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. from Repertoire Partners LP, Velan Capital Investment Management LP and others.	22-08-09	CI
Radius Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Radius Health, Inc. and Teijin Pharma Limited Enter into an Amendment to License and Development Agreement	22-08-02	CI
Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health	22-07-11	CI
Radius Health Inc Issues an Investor Presentation to Shareholders	22-07-08	CI
Radius Health Solicits Proxies from Shareholders	22-07-07	CI
Radius Health Says First Patient Randomized in Trial of Prader-Willi Syndrome Symptoms	22-07-07	MT
Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome	22-07-07	CI
Radius Health, Inc Provides Information to the Shareholders	22-06-27	CI
Velan Capital Investment Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital	22-06-24	CI
SVB Securities Adjusts Radius Health's Price Target to $10 from $7, Keeps Market Perform Rating	22-06-24	MT

Chart Radius Health, Inc.

Duration

Period

More charts

Company Profile

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs